Treatment of hepatocellular carcinoma with sorafenib: focus on special populations and adverse event
Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma. It inhibits downstream signaling of VEGFR-2, PDGFR, c-Kit receptors and BRAF. Over the last four years c...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10. September 2012
|
| In: |
Zeitschrift für Gastroenterologie
Year: 2012, Jahrgang: 50, Heft: 9, Pages: 1018-1027 |
| ISSN: | 1439-7803 |
| DOI: | 10.1055/s-0032-1312771 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1055/s-0032-1312771 Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1312771 
|
| Verfasserangaben: | E. Schott, M.P. Ebert, J. Trojan |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578541999 | ||
| 003 | DE-627 | ||
| 005 | 20220814215559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180814s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0032-1312771 |2 doi | |
| 035 | |a (DE-627)1578541999 | ||
| 035 | |a (DE-576)508541999 | ||
| 035 | |a (DE-599)BSZ508541999 | ||
| 035 | |a (OCoLC)1341016877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schott, Eckart |d 1969- |e VerfasserIn |0 (DE-588)120137496 |0 (DE-627)696415143 |0 (DE-576)29205873X |4 aut | |
| 245 | 1 | 0 | |a Treatment of hepatocellular carcinoma with sorafenib |b focus on special populations and adverse event |c E. Schott, M.P. Ebert, J. Trojan |
| 246 | 3 | 0 | |a Therapie des hepatozellulären Karzinoms$dFokus auf besondere Indikationen und Management von Nebenwirkungen |
| 264 | 1 | |c 10. September 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Publikationsdatum: 10. September 2012 (online) | ||
| 500 | |a Gesehen am 14.08.2018 | ||
| 520 | |a Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma. It inhibits downstream signaling of VEGFR-2, PDGFR, c-Kit receptors and BRAF. Over the last four years comprehensive experience with sorafenib in this indication has been accumulated. In this review we discuss the current data on the use of sorafenib in patients with advanced HCC including special patient populations such as patients with impaired liver function, patients after transplantation, and others. The most frequent side-effects and practical tips on how to manage them are discussed in detail. In addition, we summarize the current experimental data on the use of sorafenib in combination treatment, e. g., together with transarterial chemoembolisation or other targeted agents. | ||
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a sorafenib | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Ebert, Matthias |d 1968- |e VerfasserIn |0 (DE-588)1030133522 |0 (DE-627)734827083 |0 (DE-576)377938432 |4 aut | |
| 700 | 1 | |a Trojanek, Joanna B. |e VerfasserIn |0 (DE-588)1067641408 |0 (DE-627)819047414 |0 (DE-576)426810899 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zeitschrift für Gastroenterologie |d Stuttgart [u.a.] : Thieme, 1997 |g 50(2012), 9, Seite 1018-1027 |h Online-Ressource |w (DE-627)326647368 |w (DE-600)2041790-1 |w (DE-576)256442215 |x 1439-7803 |7 nnas |a Treatment of hepatocellular carcinoma with sorafenib focus on special populations and adverse event |
| 773 | 1 | 8 | |g volume:50 |g year:2012 |g number:9 |g pages:1018-1027 |g extent:10 |a Treatment of hepatocellular carcinoma with sorafenib focus on special populations and adverse event |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0032-1312771 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1312771 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180814 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1030133522 |a Ebert, Matthias |m 1030133522:Ebert, Matthias |d 60000 |d 61100 |e 60000PE1030133522 |e 61100PE1030133522 |k 0/60000/ |k 1/60000/61100/ |p 2 | ||
| 999 | |a KXP-PPN1578541999 |e 3020835682 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["E. Schott, M.P. Ebert, J. Trojan"]},"recId":"1578541999","id":{"eki":["1578541999"],"doi":["10.1055/s-0032-1312771"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"10. September 2012"}],"physDesc":[{"extent":"10 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"family":"Schott","given":"Eckart","role":"aut","display":"Schott, Eckart"},{"display":"Ebert, Matthias","role":"aut","given":"Matthias","family":"Ebert"},{"role":"aut","given":"Joanna B.","family":"Trojanek","display":"Trojanek, Joanna B."}],"title":[{"title_sort":"Treatment of hepatocellular carcinoma with sorafenib","subtitle":"focus on special populations and adverse event","title":"Treatment of hepatocellular carcinoma with sorafenib"}],"relHost":[{"language":["ger"],"pubHistory":["Nachgewiesen 38.2000 -"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 07.11.2013"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Zeitschrift für Gastroenterologie","subtitle":"offizielles Organ: Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten mit Sektion Gastroenterologische Endoskopie ; Österreichische Gesellschaft für Gastroenterologie und Hepatologie ; Ungarische Gesellschaft für Gastroenterologie und Hepatologie = German journal of gastroenterology","title_sort":"Zeitschrift für Gastroenterologie"}],"titleTranslated":[{"translated":"German journal of gastroenterology"}],"disp":"Treatment of hepatocellular carcinoma with sorafenib focus on special populations and adverse eventZeitschrift für Gastroenterologie","recId":"326647368","part":{"pages":"1018-1027","volume":"50","extent":"10","text":"50(2012), 9, Seite 1018-1027","year":"2012","issue":"9"},"origin":[{"dateIssuedKey":"1997","publisher":"Thieme","dateIssuedDisp":"1997-","publisherPlace":"Stuttgart [u.a.]"}],"id":{"eki":["326647368"],"issn":["1439-7803"],"zdb":["2041790-1"],"doi":["10.1055/s-00000094"]}}],"note":["Publikationsdatum: 10. September 2012 (online)","Gesehen am 14.08.2018"]} | ||
| SRT | |a SCHOTTECKATREATMENTO1020 | ||